These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3292 related articles for article (PubMed ID: 30786725)

  • 21. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
    Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M
    Circulation; 2024 Feb; 149(6):450-462. PubMed ID: 37952217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
    Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
    Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
    Blood AJ; Chang LS; Hassan S; Chasse J; Stern G; Gabovitch D; Zelle D; Colling C; Aronson SJ; Figueroa C; Collins E; Ruggiero R; Zacherle E; Noone J; Robar C; Plutzky J; Gaziano TA; Cannon CP; Wexler DJ; Scirica BM
    Circulation; 2024 Jun; 149(23):1802-1811. PubMed ID: 38583146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.
    Zhou Z; Zheng M; Zuo Z; Wu T
    ESC Heart Fail; 2024 Jun; 11(3):1647-1656. PubMed ID: 38419382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
    Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
    Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
    Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
    Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
    Pinto LC; Rados DV; Remonti LR; Viana LV; Pulz GT; Carpena MP; Borges RP; Marobin R; Beretta MV; Pedrollo EF; Londero TM; Machry R; Janeczko L; Moehlecke M; Falcetta MR; Bauer AC; Silveiro SP; Gerchman F; Rodrigues TC; Kramer CK; Bertoluci MC; Leitão CB
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32797182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
    Lyu B; Grams ME; Chang A; Inker LA; Coresh J; Shin JI
    Am J Cardiol; 2022 Feb; 165():124-130. PubMed ID: 34937658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
    Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
    Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
    Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.
    McKee A; Al-Khazaali A; Albert SG
    J Endocr Soc; 2020 May; 4(5):bvaa037. PubMed ID: 32342023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Cardoso P; Young KG; Nair ATN; Hopkins R; McGovern AP; Haider E; Karunaratne P; Donnelly L; Mateen BA; Sattar N; Holman RR; Bowden J; Hattersley AT; Pearson ER; Jones AG; Shields BM; McKinley TJ; Dennis JM;
    Diabetologia; 2024 May; 67(5):822-836. PubMed ID: 38388753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.
    Lin YH; Lin CH; Lin YC; Huang YY; Tai AS; Fu SC; Lin SH
    Endocr Pract; 2024 May; 30(5):424-430. PubMed ID: 38325629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.
    Rodriguez-Valadez JM; Tahsin M; Masharani U; Park M; Hunink MGM; Yeboah J; Li L; Weber E; Berkalieva A; Avezaat L; Max W; Fleischmann KE; Ferket BS
    J Am Heart Assoc; 2024 Feb; 13(4):e032463. PubMed ID: 38362889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
    Ferreira JP; Saraiva F; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
    Diabetes Obes Metab; 2023 Jun; 25(6):1495-1502. PubMed ID: 36722252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 165.